Johnson & Johnson (NYSE:JNJ) Shares Sold by Lawson Kroeker Investment Management Inc. NE

Lawson Kroeker Investment Management Inc. NE lowered its position in Johnson & Johnson (NYSE:JNJGet Rating) by 8.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 57,490 shares of the company’s stock after selling 5,100 shares during the quarter. Johnson & Johnson accounts for approximately 3.4% of Lawson Kroeker Investment Management Inc. NE’s investment portfolio, making the stock its 8th largest position. Lawson Kroeker Investment Management Inc. NE’s holdings in Johnson & Johnson were worth $10,205,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sound Income Strategies LLC increased its position in Johnson & Johnson by 12.3% during the 2nd quarter. Sound Income Strategies LLC now owns 36,636 shares of the company’s stock valued at $6,503,000 after purchasing an additional 4,020 shares during the period. Flaharty Asset Management LLC increased its position in Johnson & Johnson by 4.4% during the 2nd quarter. Flaharty Asset Management LLC now owns 12,802 shares of the company’s stock valued at $2,272,000 after purchasing an additional 537 shares during the period. Symmetry Partners LLC increased its position in Johnson & Johnson by 34.2% during the 2nd quarter. Symmetry Partners LLC now owns 31,253 shares of the company’s stock valued at $5,548,000 after purchasing an additional 7,971 shares during the period. McNaughton Wealth Management LLC increased its position in Johnson & Johnson by 35.9% during the 2nd quarter. McNaughton Wealth Management LLC now owns 3,716 shares of the company’s stock valued at $660,000 after purchasing an additional 981 shares during the period. Finally, Thrive Wealth Management LLC increased its position in Johnson & Johnson by 6.7% during the 2nd quarter. Thrive Wealth Management LLC now owns 16,831 shares of the company’s stock valued at $2,988,000 after purchasing an additional 1,062 shares during the period. Institutional investors and hedge funds own 68.59% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $166.28 on Tuesday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The business’s fifty day moving average is $168.96 and its 200 day moving average is $174.33. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. The stock has a market cap of $437.18 billion, a P/E ratio of 24.20, a P/E/G ratio of 2.99 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. During the same period last year, the business earned $2.48 EPS. The business’s revenue was up 3.0% on a year-over-year basis. Sell-side analysts anticipate that Johnson & Johnson will post 10.7 earnings per share for the current fiscal year.

Johnson & Johnson declared that its Board of Directors has authorized a stock repurchase plan on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 1.2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.72%. The ex-dividend date was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating on the stock. UBS Group cut their price target on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. SVB Leerink cut their price target on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Citigroup cut their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Finally, Wells Fargo & Company increased their price target on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $189.78.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.